Key result
Low-dose sacubitril/valsartan prevents CTRCD vs standard care in early breast cancer, avoiding a ~26% incidence.
Why the study?
Cancer therapy-related cardiac dysfunction adversely affects outcomes in cancer, but the cardioprotective effects of sacubitril/valsartan in preventing it remain underexplored.
Does sacubitril/valsartan prevent cancer therapy-related cardiac dysfunction in treatment-naïve patients with early breast cancer receiving adjuvant therapy?
RCT (n=100)
1:4 ratio
Does sacubitril/valsartan prevent cancer therapy-related cardiac dysfunction in treatment-naïve patients with early breast cancer receiving adjuvant therapy?
Absolute Event Rate: 0% vs 26.3%
p-value: p=0.006
Low-dose sacubitril/valsartan significantly prevented cancer therapy-related cardiac dysfunction, primarily measured by GLS decline, in early breast cancer patients undergoing adjuvant therapy.
Supports low-dose sacubitril/valsartan for CTRCD prevention in early breast cancer; first RCT evidence extending ARNI into cardio-oncology.
Aims Cancer therapy-related cardiac dysfunction (CTRCD) can adversely affect clinical outcomes in patients with cancer. The cardioprotective effects of sacubitril/valsartan in preventing CTRCD remain underexplored. This study aimed to evaluate the cardioprotective effects of sacubitril/valsartan in preventing CTRCD in patients with early breast cancer during the first year after adjuvant therapy. Methods and results One hundred newly diagnosed treatment-naïve patients with early breast cancer (50.4 ± 8.5 years, 98% women) were enrolled prospectively between May 2021 and July 2023. Participants were randomized at a 1:4 ratio to receive sacubitril/valsartan, starting 3 days before cancer therapy at an initial dose of 12.25/12.75 mg twice daily, titrated to a maximum dose of 24.5/25.5 mg twice daily (n = 20), or standard care with monitoring and initiation of standard therapies upon CTRCD occurrence (n = 80) for 12 months. There were no significant differences in the baseline demographic characteristics between the two groups. The mean doxorubicin-equivalent dose was 276.0 ± 48.5 mg/m2 in the sacubitril/valsartan group and 269.5 ± 57.9 mg/m2 in the standard care group (p = 0.175). The primary endpoint was the development of CTRCD, defined as a relative ≥15% decline in global longitudinal strain (GLS) or a reduction in left ventricular ejection fraction by ≥10 percentage points to below 50%. Of the 100 randomized patients, 95 (95%) completed the trial. No patient in the sacubitril/valsartan group developed CTRCD, whereas 21 patients (26.3%) in the standard care group did (p = 0.006). All events of CTRCD were identified based on significant decline in GLS. Conclusions Low-dose sacubitril/valsartan may prevent CTRCD in treatment-naïve patients with early breast cancer undergoing adjuvant therapy within the first year. Large phase III clinical trials are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2025) conducted an RCT in early breast cancer (n=100). sacubitril/valsartan vs. standard care was evaluated on development of CTRCD, defined as a relative ≥15% decline in global longitudinal strain (GLS) or a reduction in left ventricular ejection fraction by ≥10 percentage points to below 50% (p=0.006). Low-dose sacubitril/valsartan prevented cancer therapy-related cardiac dysfunction compared to standard care in treatment-naïve patients with early breast cancer (0% vs 26.3%; p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: